CR20140151A - Compuestos de piperidina útiles para el tratamiento de enfermedades neurodegenerativas-1-arilcarbolino-4-oxya - Google Patents
Compuestos de piperidina útiles para el tratamiento de enfermedades neurodegenerativas-1-arilcarbolino-4-oxyaInfo
- Publication number
- CR20140151A CR20140151A CR20140151A CR20140151A CR20140151A CR 20140151 A CR20140151 A CR 20140151A CR 20140151 A CR20140151 A CR 20140151A CR 20140151 A CR20140151 A CR 20140151A CR 20140151 A CR20140151 A CR 20140151A
- Authority
- CR
- Costa Rica
- Prior art keywords
- arilcarbolino
- oxya
- treatment
- neurodegenerative diseases
- compounds useful
- Prior art date
Links
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical class C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 title 1
- 208000015122 neurodegenerative disease Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011222741 | 2011-10-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20140151A true CR20140151A (es) | 2014-05-26 |
Family
ID=47143241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20140151A CR20140151A (es) | 2011-10-07 | 2014-04-03 | Compuestos de piperidina útiles para el tratamiento de enfermedades neurodegenerativas-1-arilcarbolino-4-oxya |
Country Status (43)
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2851087C (en) | 2011-10-07 | 2019-09-24 | Takeda Pharmaceutical Company Limited | 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases |
| WO2014061676A1 (ja) | 2012-10-16 | 2014-04-24 | 武田薬品工業株式会社 | 複素環化合物 |
| WO2014092100A1 (ja) | 2012-12-11 | 2014-06-19 | 武田薬品工業株式会社 | 複素環化合物 |
| RS67266B1 (sr) | 2013-03-13 | 2025-10-31 | Sage Therapeutics Inc | Neuroaktivni steroidi i postupci za njihovu upotrebu |
| EP2982670B1 (en) | 2013-04-04 | 2018-11-07 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| US9598398B2 (en) | 2013-04-04 | 2017-03-21 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| JP6533799B2 (ja) * | 2014-06-09 | 2019-06-19 | 武田薬品工業株式会社 | 放射標識された化合物 |
| ES2970222T3 (es) | 2014-06-18 | 2024-05-27 | Sage Therapeutics Inc | Oxiesteroles y procedimientos de uso de los mismos |
| CN104803922A (zh) * | 2015-03-14 | 2015-07-29 | 长沙深橙生物科技有限公司 | 一种嘧啶衍生物的制备方法 |
| MX390271B (es) | 2015-07-06 | 2025-03-20 | Sage Therapeutics Inc | Oxiesteroles y metodos de uso de los mismos |
| FI3828194T3 (fi) | 2015-07-06 | 2025-07-17 | Sage Therapeutics Inc | Oxysteroleita ja menetelmiä niiden käyttämiseksi |
| EP3363796B1 (en) * | 2015-10-16 | 2021-04-07 | Takeda Pharmaceutical Company Limited | Method for producing heterocyclic compound |
| GB201604029D0 (en) | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
| US20190330259A1 (en) | 2016-04-01 | 2019-10-31 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| WO2017193046A1 (en) | 2016-05-06 | 2017-11-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| WO2017195894A1 (ja) * | 2016-05-13 | 2017-11-16 | 日産化学工業株式会社 | ２－アセチルピリジン化合物の製造方法 |
| JP7149266B2 (ja) | 2016-09-30 | 2022-10-06 | セージ セラピューティクス， インコーポレイテッド | Ｃ７置換オキシステロールおよびｎｍｄａモジュレーターとしての方法 |
| GB201617758D0 (en) | 2016-10-20 | 2016-12-07 | Almac Discovery Limited | Pharmaceutical compounds |
| CA3073925A1 (en) | 2017-08-31 | 2019-03-07 | Takeda Pharmaceutical Company Limited | Treatment of cns conditions |
| WO2020027344A1 (en) | 2018-08-03 | 2020-02-06 | Takeda Pharmaceutical Company Limited | Ch24h inhibitors for mdd use |
| WO2020059894A1 (en) | 2018-09-20 | 2020-03-26 | Takeda Pharmaceutical Company Limited | CH24H Inhibitors For Pain Use |
| TWI855081B (zh) * | 2019-05-24 | 2024-09-11 | 美商賽吉醫療公司 | 化合物、組合物及使用方法 |
| US12029718B2 (en) | 2021-11-09 | 2024-07-09 | Cct Sciences, Llc | Process for production of essentially pure delta-9-tetrahydrocannabinol |
| IL303170A (en) * | 2020-11-25 | 2023-07-01 | Sage Therapeutics Inc | 4-fluoro-(4-(4-benzyl)piperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl)methanone derivatives and similar compounds as cyp46a1 inhibitors for the treatment of neurodegenerative disorders |
| AU2022291395A1 (en) | 2021-06-11 | 2024-01-04 | Sage Therapeutics, Inc. | Neuroactive steroid for the treatment of alzheimer's disease |
| KR20240121239A (ko) * | 2021-12-17 | 2024-08-08 | 아티라 파마, 인코포레이티드 | 질환 치료를 위한 이환식 화합물의 용도 |
| CN116444477B (zh) * | 2023-04-04 | 2026-01-02 | 宁波九胜创新医药科技有限公司 | 一种溴代胡椒环羧酸的制备方法及其用途 |
| WO2025019590A2 (en) * | 2023-07-18 | 2025-01-23 | The General Hospital Corporation | Proteolysis targeting chimeras for treating neurodegeneration |
| WO2025126159A1 (en) | 2023-12-15 | 2025-06-19 | Takeda Pharmaceutical Company Limited | A method for treating a neurological disease in a recreational drug user |
| WO2025257799A1 (en) | 2024-06-14 | 2025-12-18 | Takeda Pharmaceutical Company Limited | Methods of treating dravet syndrome |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5854204A (en) | 1995-03-14 | 1998-12-29 | Praecis Pharmaceuticals, Inc. | Aβ peptides that modulate β-amyloid aggregation |
| CA2262453A1 (en) | 1996-08-27 | 1998-03-05 | Praecis Pharmaceuticals Incorporated | Modulators of .beta.-amyloid peptide aggregation comprising d-amino acids |
| CA2374346C (en) | 1999-06-28 | 2010-06-22 | Jordan J. N. Tang | Inhibitors of memapsin 2 and use thereof |
| AR035016A1 (es) | 1999-08-25 | 2004-04-14 | Takeda Chemical Industries Ltd | Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima. |
| ATE479429T1 (de) | 2000-04-28 | 2010-09-15 | Takeda Pharmaceutical | Antagonisten des melanin-konzentrierenden hormons |
| CA2408913A1 (en) | 2000-05-16 | 2001-11-22 | Takeda Chemical Industries, Ltd. | Melanin-concentrating hormone antagonist |
| AU2002248432A1 (en) | 2001-02-14 | 2002-08-28 | Sankyo Company, Limited | Oxazole derivatives, their preparation and their use as cytokine inhibitors |
| CA2445568A1 (en) | 2001-04-27 | 2002-11-07 | Vertex Pharmaceuticals Incorporated | Triazole-derived kinase inhibitors and uses thereof |
| US20030195192A1 (en) | 2002-04-05 | 2003-10-16 | Fortuna Haviv | Nicotinamides having antiangiogenic activity |
| US20040014744A1 (en) | 2002-04-05 | 2004-01-22 | Fortuna Haviv | Substituted pyridines having antiangiogenic activity |
| AU2003288231A1 (en) | 2002-12-13 | 2004-07-09 | Bayer Healthcare Ag | Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease |
| DOP2005000039A (es) | 2004-03-26 | 2005-10-31 | Aventis Pharma Inc | Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)- piperidin-1-il]-(4-bomo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos |
| US20060167044A1 (en) | 2004-12-20 | 2006-07-27 | Arnaiz Damian O | Piperidine derivatives and their use as anti-inflammatory agents |
| JPWO2006137465A1 (ja) | 2005-06-24 | 2009-01-22 | 塩野義製薬株式会社 | 含窒素複素環誘導体 |
| WO2007062999A2 (en) | 2005-11-30 | 2007-06-07 | F. Hoffmann-La Roche Ag | 1,5-substituted indol-2-yl amide derivatives |
| CA2634547C (en) | 2005-12-20 | 2016-10-11 | Bristol-Myers Squibb Company | Stable ctla4 formulation for subcutaneous administration |
| AU2007275301A1 (en) * | 2006-07-20 | 2008-01-24 | Amgen Inc. | Substituted azole aromatic heterocycles as inhibitors of 11-beta-HSD-1 |
| KR101476472B1 (ko) | 2007-03-30 | 2015-01-05 | 암브룩스, 인코포레이티드 | 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도 |
| WO2008134547A1 (en) | 2007-04-25 | 2008-11-06 | Xenon Pharmaceuticals Inc. | Methods of using hydroxycyclohexane and hydroxypiperidine compounds in treating sodium channel-mediated diseases or conditions |
| WO2008153722A1 (en) | 2007-05-22 | 2008-12-18 | The Board Of Regents Of The University Of Texas System | Post-translational regulation of catalytic activities of cytochrome p450 46a1 and uses thereof |
| WO2009117421A2 (en) | 2008-03-17 | 2009-09-24 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| BRPI0916920A2 (pt) | 2008-08-22 | 2015-11-24 | Sanofi Aventis | 4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-[7-fluoro-1-(2-metóxi-etil)-4-trifluorometóxi-1h-indol-3-il]-metanona como inibidor de triptase de mastócito, seu uso e método de preparação, bem como forma cristalina |
| WO2010075376A2 (en) | 2008-12-23 | 2010-07-01 | Abbott Laboratories | Anti-viral compounds |
| DE102009022896A1 (de) | 2009-05-27 | 2010-12-02 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Piperidine |
| DE102009022894A1 (de) | 2009-05-27 | 2010-12-02 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Piperidine |
| US9051296B2 (en) | 2009-11-16 | 2015-06-09 | Raqualia Pharma Inc. | Aryl carboxamide derivatives as TTX-S blockers |
| JP5316468B2 (ja) | 2010-04-09 | 2013-10-16 | 株式会社豊田自動織機 | リアクトル構造 |
| KR101764952B1 (ko) | 2010-07-29 | 2017-08-03 | 리겔 파마슈티칼스, 인크. | Ａｍｐｋ-활성화 헤테로시클릭 화합물 및 그의 사용 방법 |
| US20140031547A1 (en) | 2010-12-14 | 2014-01-30 | Electrophoretics Limited | CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODE-GENERATIVE DISEASES SUCH AS TAUOPATHIES |
| CA2851087C (en) * | 2011-10-07 | 2019-09-24 | Takeda Pharmaceutical Company Limited | 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases |
-
2012
- 2012-10-03 CA CA2851087A patent/CA2851087C/en active Active
- 2012-10-03 PL PL12781479T patent/PL2763979T3/pl unknown
- 2012-10-03 ES ES12781479T patent/ES2716531T3/es active Active
- 2012-10-03 EP EP12781479.6A patent/EP2763979B1/en active Active
- 2012-10-03 HR HRP20190491TT patent/HRP20190491T1/hr unknown
- 2012-10-03 AR ARP120103691A patent/AR088226A1/es active IP Right Grant
- 2012-10-03 MY MYPI2014700836A patent/MY176126A/en unknown
- 2012-10-03 SG SG2014010417A patent/SG2014010417A/en unknown
- 2012-10-03 ME MEP-2019-69A patent/ME03372B/me unknown
- 2012-10-03 UA UAA201404855A patent/UA115133C2/uk unknown
- 2012-10-03 SI SI201231548T patent/SI2763979T1/sl unknown
- 2012-10-03 GE GEAP201213457A patent/GEP201706608B/en unknown
- 2012-10-03 PE PE2014000466A patent/PE20141120A1/es active IP Right Grant
- 2012-10-03 PH PH1/2014/500759A patent/PH12014500759A1/en unknown
- 2012-10-03 HU HUE12781479A patent/HUE043171T2/hu unknown
- 2012-10-03 TW TW101136475A patent/TWI582084B/zh active
- 2012-10-03 JP JP2014513813A patent/JP6117191B2/ja active Active
- 2012-10-03 EA EA201490747A patent/EA025662B1/ru not_active IP Right Cessation
- 2012-10-03 SM SM20190173T patent/SMT201900173T1/it unknown
- 2012-10-03 LT LTEP12781479.6T patent/LT2763979T/lt unknown
- 2012-10-03 TR TR2019/02788T patent/TR201902788T4/tr unknown
- 2012-10-03 DK DK12781479.6T patent/DK2763979T3/en active
- 2012-10-03 US US13/633,995 patent/US8648079B2/en active Active
- 2012-10-03 AU AU2012321815A patent/AU2012321815B2/en active Active
- 2012-10-03 UY UY0001034365A patent/UY34365A/es not_active Application Discontinuation
- 2012-10-03 BR BR122022001219-1A patent/BR122022001219B1/pt active IP Right Grant
- 2012-10-03 KR KR1020147011963A patent/KR101967497B1/ko active Active
- 2012-10-03 AP AP2014007606A patent/AP2014007606A0/xx unknown
- 2012-10-03 BR BR112014007257-4A patent/BR112014007257B1/pt active IP Right Grant
- 2012-10-03 MX MX2014004253A patent/MX360706B/es active IP Right Grant
- 2012-10-03 PT PT12781479T patent/PT2763979T/pt unknown
- 2012-10-03 WO PCT/JP2012/076257 patent/WO2013054822A1/en not_active Ceased
- 2012-10-03 US US14/349,201 patent/US9193709B2/en active Active
- 2012-10-03 RS RS20190304A patent/RS58470B1/sr unknown
- 2012-10-03 CN CN201280049068.8A patent/CN103842356B/zh active Active
-
2013
- 2013-07-17 US US13/944,000 patent/US8865717B2/en active Active
- 2013-07-17 US US13/944,042 patent/US8871766B2/en active Active
-
2014
- 2014-03-24 IL IL231678A patent/IL231678A/en active IP Right Grant
- 2014-03-25 TN TNP2014000122A patent/TN2014000122A1/en unknown
- 2014-04-02 ZA ZA2014/02424A patent/ZA201402424B/en unknown
- 2014-04-02 CL CL2014000806A patent/CL2014000806A1/es unknown
- 2014-04-03 CR CR20140151A patent/CR20140151A/es unknown
- 2014-04-04 DO DO2014000064A patent/DOP2014000064A/es unknown
- 2014-04-29 EC ECSP14013329 patent/ECSP14013329A/es unknown
- 2014-05-02 CO CO14094354A patent/CO6940432A2/es unknown
- 2014-05-04 MA MA36973A patent/MA35623B1/fr unknown
-
2015
- 2015-09-08 US US14/847,703 patent/US9440990B2/en active Active
-
2016
- 2016-07-28 US US15/221,761 patent/US9586930B2/en active Active
-
2017
- 2017-02-03 US US15/424,075 patent/US10144743B2/en active Active
-
2018
- 2018-11-19 US US16/194,540 patent/US10273245B2/en active Active
-
2019
- 2019-03-18 CY CY20191100324T patent/CY1121549T1/el unknown
- 2019-04-11 US US16/381,163 patent/US10550129B2/en active Active
-
2020
- 2020-02-03 US US16/779,797 patent/US10717748B2/en active Active
- 2020-07-20 US US16/933,092 patent/US11174272B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6940432A2 (es) | Compuestos de 1-arilcarbonilo-4-oxi-piperidina útiles para el tratamiento de enfermedades neurodegenerativas | |
| CO6821964A2 (es) | Compuestos para el tratamiento de la adicción | |
| SMT201600308B (it) | Composti di benzene arile-o eteroarile-sostituiti | |
| CO6801733A2 (es) | Silicato de zirconio microporoso para el tratamiento de la hipercalemia | |
| CO6900145A2 (es) | Compuesto de ciclopropanoamina | |
| CO7061081A2 (es) | Derivados macrocíclicos para el tratamiento de enfermedades | |
| PL3202421T3 (pl) | Emulsje o/w zawierające semifluorowane alkany | |
| BR112014012016A2 (pt) | compostos | |
| HRP20180809T1 (hr) | Inhibicijski spojevi metaloenzima | |
| CO6910197A2 (es) | Compuestos novedosos | |
| CO6930366A2 (es) | Método para el tratamiento de vhc | |
| CO6960541A2 (es) | Nueva composición farmacéutica resistente al abuso para el tratamiento de la dependencia de opioides | |
| EP2704575A4 (en) | COMPOSITIONS FOR INHIBITING INSECT CONTROL | |
| DK3395357T3 (da) | Sammensætning til kontrolleret ovariestimulering | |
| EP2730573A4 (en) | METHYLPIPERIDINDERIVAT | |
| LTC3246325I2 (lt) | 2-acilaminotiazolo junginio kristalai | |
| DK2706977T3 (da) | Dispergeringsmidler med biobaserede forbindelser | |
| BR112014008067A2 (pt) | compostos antibacterianos | |
| BR112014009319A2 (pt) | compostos farmacêuticos | |
| CO6821965A2 (es) | 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia | |
| BR112013033306A2 (pt) | compostos orgânicos | |
| HUE046327T2 (hu) | Tisztítási eljárás foszfaplatin vegyületekhez | |
| IL238592B (en) | Compounds for treatment of liver diseases | |
| BR112013022508A2 (pt) | novos compostos de azaespirodecanona | |
| CU24076B1 (es) | Composición para el control de patógenos |